Compare · MRK vs SION
MRK vs SION
Side-by-side comparison of Merck & Company Inc. (MRK) and Sionna Therapeutics Inc. (SION): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRK and SION operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $364.26B, about 2418.2x SION ($150.6M).
- MRK has been more active in the news (18 items in the past 4 weeks vs 5 for SION).
- MRK has more recent analyst coverage (25 ratings vs 16 for SION).
- Company
- Merck & Company Inc.
- Sionna Therapeutics Inc.
- Price
- -
- -
- Market cap
- $364.26B
- $150.6M
- 1M return
- +1.70%
- -
- 1Y return
- +59.16%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 18
- 5
- Recent ratings
- 25
- 16
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Latest MRK
- SEC Form 13F-HR filed by Merck & Company Inc.
- Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season
- Merck to Participate in the Jefferies Global Healthcare Conference in London
- Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis
- FDA Approval for WELIREG issued to MERCK SHARP DOHME
- SEC Form 10-Q filed by Merck & Company Inc.
- Stocks Surged Across the Board Today, and Biotech Brought Its Own Earnings Story
- SEC Form 4 filed by Director Diaz Paul J
- New insider Diaz Paul J claimed ownership of 296 shares (SEC Form 3)
- Merck Initiates Phase 3 Study Evaluating Ohtuvayre® (ensifentrine) for the Prevention of COPD Exacerbations in Adult Patients Receiving Standard of Care With a History of Exacerbations
Latest SION
- SEC Form 10-Q filed by Sionna Therapeutics Inc.
- Sionna Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Sionna Therapeutics Reports Third Quarter 2026 Financial Results
- SEC Form SCHEDULE 13G filed by Sionna Therapeutics Inc.
- Sionna Therapeutics to Participate in Upcoming November 2026 Investor Conferences
- Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference
- Director Ra Capital Management, L.P. sold $21,835,018 worth of shares (3,448,811 units at $6.33) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by Sionna Therapeutics Inc.
- CFO and CBO Ridloff Elena was granted 94,537 shares, increasing direct ownership by 245% to 133,069 units (SEC Form 4)
- CMO and Head of R&D Mckee Charlotte was granted 100,000 shares, increasing direct ownership by 352% to 128,415 units (SEC Form 4)